Why the study?
Does high-dose atorvastatin alter USPIO uptake in carotid plaques as measured by quantitative T2 MRI compared to low-dose atorvastatin in patients with >40% carotid stenosis?
Does high-dose atorvastatin alter USPIO uptake in carotid plaques as measured by quantitative T2 MRI compared to low-dose atorvastatin in patients with >40% carotid stenosis?
Quantitative T2 MRI can effectively measure changes in USPIO uptake in carotid plaques in response to different doses of statin therapy.
Answers are grounded in this paper and cite their sources.
High-dose atorvastatin may reduce USPIO-detectable inflammation in carotid stenosis; extends RCT evidence for quantitative T2 MRI as a responsive plaque biomarker.
This study investigates T(2)* quantification in carotid plaques before and after the administration of ultrasmall superparamagnetic iron oxide particles (USPIOs) in a cohort of patients receiving statin therapy. Phantom studies were performed using gels with varying concentrations of USPIOs. In the phantom study, 12 gels were prepared with a range of freely distributed concentrations of USPIO nanoparticles (0-0.05 mg/mL). Relative signal intensity measurements were obtained from a T(2)*-weighted sequence as well as quantitative T(2)* (qT(2)*) measurements. In the patient study, 40 patients with >40% carotid stenosis were randomised to low- and high-dose statin therapy (10 and 80 mg of atorvastatin). Pre- and post- (36 h) USPIO-enhanced MRI were performed at baseline, and at 6 and 12 weeks. A linear mixed-effects model was applied to account for the inherent correlation of multiple-plaque measurements from the same patient and to assess dose-response differences to statin therapy. In the phantom study, the T(2)*-weighted sequence demonstrated an initial increase (T(1) effect), followed by a decrease (T(2)* effect), in relative signal intensity with increasing concentrations of USPIO. The qT(2)* values decreased exponentially with increasing concentrations of USPIO. In the patient study, there was a highly significant difference in post-USPIO T(2)* measurements in plaques between the low- and high-dose statin groups. This was observed for both the difference in qT(2)* measurements (post-USPIO minus pre-USPIO) (p < 0.001) and for qT(2)* post-USPIO only (p < 0.001). The post-USPIO qT(2)* values were as follows: baseline: low dose, 13.6 ± 5.5 ms; high dose, 12.9 ± 6.2 ms; 6 weeks: low dose, 13.3 ± 6.7 ms; high dose, 14.3 ± 7.7 ms; 12 weeks: low dose, 14.0 ± 7.6 ms; high dose, 18.3 ± 11.2 ms. It can be concluded that qT(2)* measurements provide an alternative method of quantifying USPIO uptake. These results also demonstrate that changes in USPIO uptake can be measured using post-USPIO imaging only.
No takes yet. Share an insight, caveat, or question.
Patterson et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: